NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NAARDEN, the Netherlands and MIAMI, March 25, 2024 -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk...

Related Keywords

Georgia ,United States ,Brooklyn ,Miami ,Florida ,Atlanta ,Naarden ,Noord Holland ,Netherlands ,Hannah Deresiewicz ,Matthew Philippe ,Newamsterdam Pharma Companynv Nasdaq ,Exchange Commission ,Company Phase ,Health Promotion ,World Congress Center ,American College Of Cardiology ,Neither The Company ,Company Contact ,American College Of Cardiology Congress ,Cardiology Congress ,National Lipid Association Scientific Sessions ,Heterozygous Familial Hypercholesterolemia ,Atherosclerotic Cardiovascular Disease ,World Congress ,Amsterdam Pharma ,Investor Relations ,Markets ,